Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.
Stein Ulve, CEO: "It is exciting to see Eevia Health listed at Spotlight Stock Market. It is a significant milestone for our Company. Now we may continue focusing on creating growth and value for all constituents of our venture."
See also: Start | Spotlight (spotlightstockmarket.com)
Information about the Eevia Health shares:
Short name: EEVIA
Share name: Eevia Health
ISIN-code: FI4000496658
Orderbook-ID: 85FD
CFI: ESVUFR
FISN: EEVIA HEALTH/SH
Organization number: 2825194-4
LEI: 743700NO7D0UA8J1MQ31
Market Segment: SPSE
MIC code: XSAT
Tick table/liquidity band #: 1 (Shares and depositary receipts)
Seinäjoki, Finland June 29, 2021
For more information, please contact:
Stein Ulve, CEO Kim Nurmi-Aro, CFO
stein.ulve@eeviahealth.com kim@eeviahealth.com
Tel.: +358 400 22 5967 +358 504 44 0717
About Eevia
Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive byproducts from food and woodindustries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.
Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January - 31st March, corresponding to 560 percent sales growth compared to the same period prior year.
The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1st through June 30th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com
Eevia Health Plc, ("Eevia" or "The Company"), has installed new capacities and automation equipment for processing and evaporation of natural plant extract liquids. As of August 1st, the newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.
Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.
Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.
The Annual General Meeting of shareholders of Eevia Health Plc was held in Seinäjoki, on June 22, 2021. Two shareholders representing 3 797 500 shares and votes (36,14% of total shares) were represented at the meeting. The AGM decided each and all the proposals from the Board of Directors as described in the Notice of Annual General Meeting, unanimously.
This is a correction to earlier press release today, which stated that the equity issue was over-subscribed by over 400%. The correct is subscribed by over 400%. Also in one media channel the MAR label was omitted by mistake in the Press release itself.
Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%).
Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%).